ADVANCED PANCREATIC CANCER: PAST, PRESENT AND FUTURE OF TREATMENT

Authors

  • Tariq Parvez Consultant Oncologist KFH Al-Madina KSA
  • Babar Parvez Consultant Oncologist KFH Al-Madina KSA, *Lahore Pakistan
  • Bakr Nasir Abdullah Consultant Oncologist KFH Al-Madina KSA, *Lahore Pakistan
  • Talal Mutaab Alharabi Consultant Oncologist KFH Al-Madina KSA, *Lahore Pakistan
  • Muhammad Imtiaz Ibrahim Consultant Oncologist KFH Al-Madina KSA, *Lahore Pakistan

Keywords:

Chemotherapy, 5-FU, gemcitabine, molecular targeting

Abstract

Pancreatic cancer is highly lethal disease that is rising in incidence. Chemotherapy based on 5-fluorouracil (5-FU) has shown to prolong survival in advanced pancreatic cancer modestly. Gemcitabine improves major symptoms and survival outcomes compared with 5-FU. Many compounds have been investigated. These compounds are based on classical mechanisms of action as well as biological therapies targeting cellular pathways, and include fluoropyrimidines, nucleoside cytidine analogues, platinum analogues, topoisomerase inhibitors, antimicrotubule agents, proteasome inhibitors, vitamin D analogues, arachidonic acid pathway inhibitors, histone deacytylator inhibitors, farnesyltransferase inhibitors, epidermal growth factor receptor therapies and many more. Out of these some have shown their promise. Many more compounds are being tested and real advances are anticipated in the near future.

 

Downloads

Download data is not yet available.

Downloads

Published

30-10-2018

Issue

Vol. 55 No. 2 (2005): June

Section

Review Articles

How to Cite

1.
Parvez T, Parvez B, Abdullah BN, Alharabi TM, Imtiaz Ibrahim M. ADVANCED PANCREATIC CANCER: PAST, PRESENT AND FUTURE OF TREATMENT. Pak Armed Forces Med J [Internet]. 2018 Oct. 30 [cited 2025 Feb. 11];55(2):146-55. Available from: https://pafmj.org/PAFMJ/article/view/1246